Phathom Pharmaceuticals, Inc. Common Stock (PHAT)
PHARMACEUTICAL PREPARATIONS
Phathom Pharmaceuticals, Inc. Common Stock (PHAT) is listed on Nasdaq, where it has traded since October 25, 2019.
- Listed On
- Nasdaq
- Listed Since
- October 25, 2019
- Employees
- 371
- Market Cap
- $577M
About Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 155 institutions reported holding PHAT, with 71.7 million shares worth $778.5 million in aggregate. The largest reported holder was Frazier Life Sciences Management,, with 12.5 million shares worth $135.3 million. Of the 5 largest holders listed below, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Frazier Life Sciences Management, | 12,466,489 | $135M | Unchanged |
| Medicxi Ventures Management (Jersey) | 7,464,572 | $81M | Unchanged |
| BlackRock | 4,525,129 | $49M | Added 11.4% |
| Invesco Ltd | 4,029,731 | $44M | Reduced 6.76% |
| Vanguard | 3,868,699 | $42M | Added 5.86% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is PHAT?
Phathom Pharmaceuticals, Inc. Common Stock (PHAT) is listed on Nasdaq, where it has traded since October 25, 2019.
Who are the largest institutional holders of PHAT?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of PHAT were Frazier Life Sciences Management,, Medicxi Ventures Management (Jersey) and BlackRock.
How many institutions own PHAT?
155 institutions reported a position in PHAT for the quarter ended June 30, 2026, worth $778.5 million in total.
Did institutions buy or sell PHAT last quarter?
Of the 5 largest reported holders, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for PHAT.
Every reported institutional holder, plus insider and congressional trades in PHAT, on SentiSense.